Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 14 02 2019
revised: 06 03 2019
accepted: 14 03 2019
entrez: 7 4 2019
pubmed: 7 4 2019
medline: 16 4 2019
Statut: ppublish

Résumé

Early-stage colorectal cancer (CRC) carries a wide range of survival probabilities. Novel biomarkers in this setting are eagerly awaited. Cancer stem cells (CSCs) are considered one of the reasons for treatment failure. This study sought to determine whether activation of pathways governing the function of CSC's could correlate with treatment outcomes. Tumor specimens from 325 patients were analyzed with immunohistochemistry (IHC) for Hedgehog and Notch pathway activation and results were correlated with prognosis. Positive Notch3 protein expression was an unfavorable prognostic factor for disease-free survival (DFS) and overall survival (OS) (HR=2.43, p=0.024 and HR=2.56, p=0.028, respectively). Activation of the Shh pathway showed univariately longer DFS (HR=0.49, p=0.032). Possible crosstalk between the two pathways was indicated. No further associations between pathway activation and outcome were evident. Apart from Notch 3, activation of the pathways, as indicated by IHC expression of their components, did not result in differences in terms of DFS or OS.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Early-stage colorectal cancer (CRC) carries a wide range of survival probabilities. Novel biomarkers in this setting are eagerly awaited. Cancer stem cells (CSCs) are considered one of the reasons for treatment failure. This study sought to determine whether activation of pathways governing the function of CSC's could correlate with treatment outcomes.
MATERIALS AND METHODS METHODS
Tumor specimens from 325 patients were analyzed with immunohistochemistry (IHC) for Hedgehog and Notch pathway activation and results were correlated with prognosis.
RESULTS RESULTS
Positive Notch3 protein expression was an unfavorable prognostic factor for disease-free survival (DFS) and overall survival (OS) (HR=2.43, p=0.024 and HR=2.56, p=0.028, respectively). Activation of the Shh pathway showed univariately longer DFS (HR=0.49, p=0.032). Possible crosstalk between the two pathways was indicated. No further associations between pathway activation and outcome were evident.
CONCLUSION CONCLUSIONS
Apart from Notch 3, activation of the pathways, as indicated by IHC expression of their components, did not result in differences in terms of DFS or OS.

Identifiants

pubmed: 30952759
pii: 39/4/2129
doi: 10.21873/anticanres.13326
doi:

Substances chimiques

Hedgehog Proteins 0
JAG1 protein, human 0
Jagged-1 Protein 0
NOTCH2 protein, human 0
NOTCH3 protein, human 0
Receptor, Notch2 0
Receptor, Notch3 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2129-2138

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Grigorios Rallis (G)

Department of Medical Oncology, School of Health Sciences, Faculty of Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Triantafyllia Koletsa (T)

Department of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Zenia Saridaki (Z)

Asklepios Oncology Department, Heraklion, Greece.

Kyriaki Manousou (K)

Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.

Georgia-Angeliki Koliou (GA)

Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.

Ioannis Kostopoulos (I)

Department of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Vassiliki Kotoula (V)

Department of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.

Thomas Makatsoris (T)

Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece.

Helen P Kourea (HP)

Department of Pathology, University Hospital of Patras, Patras, Greece.

Georgia Raptou (G)

Department of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Sofia Chrisafi (S)

Asklepios Oncology Department, Heraklion, Greece.

Epaminontas Samantas (E)

Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.

Kleo Papaparaskeva (K)

Department of Pathology, General Hospital Konstantopouleio Agia Olga, Athens, Greece.

Elissavet Pazarli (E)

Department of Pathology, School of Health Sciences, Faculty of Medicine Thessaloniki, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Pavlos Papakostas (P)

Oncology Unit, Hippokration Hospital, Athens, Greece.

Georgia Kafiri (G)

Department of Pathology, Hippokration Hospital, Athens, Greece.

Davide Mauri (D)

Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece.

Alexandra Papoudou-Bai (A)

Department of Pathology, Ioannina University Hospital, Ioannina, Greece.

Christos Christodoulou (C)

Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.

Kalliopi Petraki (K)

Pathology Department, Metropolitan Hospital, Piraeus, Greece.

Nikolaos Dombros (N)

Aristotle University of Thessaloniki, Thessaloniki, Greece.

Dimitrios Pectasides (D)

Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece.

George Fountzilas (G)

Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece fountzil@auth.gr.
Aristotle University of Thessaloniki, Thessaloniki, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH